Infections, Bacterial Clinical Trial
Official title:
A Phase I, Randomized, Double-Blind (Sponsor Unblinded), Single-Center, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single and Repeat Intravenous Doses of GSK3342830 in Healthy Adult Subjects
A phase I, first-time-in-human (FTIH), randomized, double-blind, placebo controlled, dose-escalation study is conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of GSK3342830 after administration of single intravenous (IV) infusion in Part 1 and repeat IV infusion in Part 2 in healthy subjects. Part 1 will investigate escalating single IV doses of GSK3342830. Part 2, will investigate escalating repeat IV doses of GSK3342830 with repeat dosing for 15 days as follows: a single IV infusion on Day 1, TID (three times a day) IV infusions on Days 2 through 14 (approximately every 8 hours), and a single IV infusion on Day 15. The planned starting GSK3342830 dose in Part 1 is 250 milligram (mg) administered as a single IV infusion. The dose is planned to increase in subsequent cohorts to 500, 1000, 2000, 4000, and less than or equal to (≤) 6000 mg. Part 1 will be divided into 6 cohorts (A-F) and each cohort will enroll 10 subjects (6 in active and 2 in placebo). Dose escalation will be conducted only if it is supported by the preliminary safety, tolerability, and PK results from the preceding dose levels in the study. The repeat dose escalation component (Part 2) of this study will be planned to be initiated after completion and evaluation of the all single dose cohorts up to and including 4000 mg.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04079790 -
Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects
|
Phase 1 | |
| Completed |
NCT01934205 -
To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944
|
Phase 1 | |
| Not yet recruiting |
NCT02177721 -
Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis
|
Phase 4 | |
| Suspended |
NCT01132417 -
In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance
|
N/A | |
| Completed |
NCT00539994 -
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
|
Phase 2 | |
| Completed |
NCT01610388 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01262885 -
A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT00427141 -
A Three-Part Study Of GSK580416 In Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04620486 -
Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial
|
N/A | |
| Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
| Not yet recruiting |
NCT06440304 -
Therapeutic Options for CRAB
|
Phase 4 | |
| Completed |
NCT02292498 -
Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections
|
N/A | |
| Completed |
NCT01587768 -
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
|
N/A | |
| Withdrawn |
NCT01039610 -
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
|
Phase 1 | |
| Completed |
NCT00259909 -
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
| Completed |
NCT00828867 -
Single Dose Escalation First Time in Human PK Study
|
Phase 1 | |
| Completed |
NCT01431989 -
Amoxicillin Bioequivalence Study Brazil - Fast
|
Phase 1 | |
| Completed |
NCT02778672 -
Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia
|
N/A | |
| Completed |
NCT00896558 -
A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02045797 -
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
|
Phase 2 |